A real-life case shows how a microbiota-based therapy can provide an effective alternative when conventional antibiotics treatments fail.<\/h2>\n
<\/p>\n
<\/p>\n
At Mikrobiomik, we are committed to turning scientific innovation into real solutions for patients. This commitment is reflected in a clinical case recently reported by El Mundo<\/strong>, describing the evolution of Ra\u00fal, an adolescent with ulcerative colitis <\/strong>whose condition was severely complicated by a recurrent Clostridioides difficile infection. After multiple relapses and failure to respond to standard antibiotic treatments, major surgery became a serious possibility.<\/p>\n
The intervention of Dr. Iago Rodr\u00edguez-Lago<\/strong>, gastroenterologist at Galdakao Hospital and a leading specialist in inflammatory bowel disease, was decisive in changing the course of the disease. Given the severity of the case, the medical team decided to administer MBK-01, a microbiota-based biological therapy,<\/strong> accessed through a compassionate use program.<\/p>\n
The outcome was remarkable: the infection was resolved in less than 48 hours, avoiding colectomy and allowing the patient to recover progressively<\/strong>. As highlighted by Dr. Rodr\u00edguez-Lago, MBK-01 has shown high efficacy even in complex patients who do not respond to conventional antibiotic treatments, significantly improving their quality of life.<\/p>\n
This real-world clinical case highlights the value of MBK-01 as an innovative, non-invasive, microbiota-based therapeutic option and underscores the potential of microbiota therapies to transform the management of severe and recurrent infections.<\/strong><\/p>\n
To read the full article, click the link below<\/p>\n
![\"MBK-01](\"https:\/\/mikrobiomik.net\/wp-content\/uploads\/mbk-01-mikrobiomik.jpg\")
<\/p>\n